Skip to content
Disclosery

Rosalind Advisors, Inc.

Follow

13F filer, CIK 1622627, TORONTO, Ontario, Canada

Rosalind Advisors, Inc. reported $292,563,470 across 39 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-13. Its ten largest share positions make up 62.15% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001622627-25-000038

Period
2025-09-30
Reported value
$293M
Holdings
39
Top 10 weight
62.15%
New
11
Sold out
9

Part of the filer group Rosalind Advisors, Inc.

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
EYPTnew+650,000$9.26M
GUTSnew+5,000,000$7.95M
ATYRnew+1,039,080$7.56M
QUREnew+125,000$7.3M
MDWDadded+341,993$6.16M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
OCULreduced-818,700-$9.57M
REPLexited-900,000-$8.36M
URGNexited-542,366-$7.43M
IDYAreduced-161,132-$4.38M
PHVSexited-223,627-$3.94M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001622627-25-000038, largest first. % of portfolio is the value over $282,974,192, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
DCTHDELCATH SYS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,650,389 shares; 2024Q4: 2,650,389 shares; 2025Q1: 2,900,389 shares; 2025Q2: 3,300,389 shares; 2025Q3: 3,300,389 shares 3,300,389$33M11.66%02026-10-13, Form 4: converted 3,627 shares on 2026-10-13 Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 400,000 shares; 2025Q3: 400,000 shares 400,000$22M7.77%0Timeline
FENCFENNEC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,259,876 shares; 2025Q1: 1,782,844 shares; 2025Q2: 2,045,644 shares; 2025Q3: 2,076,840 shares 2,076,840$19.4M6.87%+31,196Timeline
VSTMVERASTEM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 900,000 shares; 2025Q1: 2,644,517 shares; 2025Q2: 2,043,563 shares; 2025Q3: 1,929,563 shares 1,929,563$17M6.02%-114,000Timeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,741,211 shares; 2025Q3: 1,807,202 shares 1,807,202$17M6%+65,991Timeline
XERSXERIS BIOPHARMA HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,104,995 shares; 2024Q4: 3,104,995 shares; 2025Q1: 2,495,986 shares; 2025Q2: 2,155,594 shares; 2025Q3: 1,795,766 shares 1,795,766$14.6M5.17%-359,828Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,654,944 shares; 2025Q1: 2,654,944 shares; 2025Q2: 2,654,944 shares; 2025Q3: 4,000,000 shares 4,000,000$14.3M5.05%+1,345,056Timeline
MDWDMEDIWOUND LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 628,050 shares; 2024Q4: 628,050 shares; 2025Q1: 506,893 shares; 2025Q2: 407,061 shares; 2025Q3: 749,054 shares 749,054$13.5M4.77%+341,993Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 595,000 shares; 2025Q2: 700,000 shares; 2025Q3: 600,000 shares 600,000$12.9M4.58%-100,000Timeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 192,974 shares; 2025Q3: 300,000 shares 300,000$12.1M4.27%+107,026Timeline
VERONA PHARMA PLCVERONA PHARMA PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 275,000 shares; 2024Q4: 150,000 shares; 2025Q1: 100,000 shares; 2025Q2: 100,000 shares; 2025Q3: 100,000 shares 100,000$10.7M3.77%0
IDYAIDEAYA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 700,000 shares; 2025Q2: 511,132 shares; 2025Q3: 350,000 shares 350,000$9.52M3.37%-161,132Timeline
NSPRINSPIREMD INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,514,046 shares; 2024Q4: 2,495,783 shares; 2025Q1: 2,274,990 shares; 2025Q2: 2,289,099 shares; 2025Q3: 3,905,743 shares 3,905,743$9.41M3.33%+1,616,644Timeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 650,000 shares 650,000$9.26M3.27%newTimeline
MIND MEDICINE MINDMED INCMIND MEDICINE MINDMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 420,000 shares; 2025Q2: 420,000 shares; 2025Q3: 750,000 shares 750,000$8.84M3.12%+330,000
HELPCYBIN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 810,918 shares; 2025Q1: 810,918 shares; 2025Q2: 810,918 shares; 2025Q3: 1,500,000 shares 1,500,000$8.84M3.12%+689,082Timeline
GUTSFRACTYL HEALTH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 5,000,000 shares 5,000,000$7.95M2.81%newTimeline
ATYRATYR PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,039,080 shares 1,039,080$7.56M2.67%newTimeline
QUREUNIQURE NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 125,000 shares 125,000$7.3M2.58%newTimeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,544,607 shares 1,544,607$5.28M1.87%newTimeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 885,000 shares; 2024Q4: 1,128,700 shares; 2025Q1: 1,218,700 shares; 2025Q2: 1,218,700 shares; 2025Q3: 400,000 shares 400,000$4.68M1.65%-818,700Timeline
TLPHTALPHERA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 758,966 shares; 2024Q4: 613,939 shares; 2025Q1: 2,003,939 shares; 2025Q2: 2,003,939 shares; 2025Q3: 4,385,757 shares 4,385,757$3.92M1.38%+2,381,818Timeline
PROFPROFOUND MED CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 485,973 shares; 2024Q4: 692,185 shares; 2025Q1: 692,185 shares; 2025Q2: 692,185 shares; 2025Q3: 692,185 shares 692,185$3.38M1.2%0Timeline
MYOMYOMO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,021,391 shares; 2024Q4: 2,998,945 shares; 2025Q1: 2,703,661 shares; 2025Q2: 3,595,788 shares; 2025Q3: 3,790,788 shares 3,790,788$3.38M1.19%+195,000Timeline
PYPDPOLYPID LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 679,168 shares; 2024Q4: 1,018,021 shares; 2025Q1: 1,018,021 shares; 2025Q2: 975,462 shares; 2025Q3: 918,668 shares 918,668$3.06M1.08%-56,794Timeline
BFRIBIOFRONTERA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 495,490 shares; 2024Q4: 811,918 shares; 2025Q1: 644,393 shares; 2025Q2: 976,448 shares; 2025Q3: 1,140,764 shares 1,140,764$1.12M0.4%+164,316Timeline
ASTRIA THERAPEUTICS INCASTRIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,542,520 shares 1,542,520$1.11M0.39%new
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 750,000 shares; 2024Q4: 1,062,500 shares; 2025Q1: 612,901 shares; 2025Q2: 300,000 shares; 2025Q3: 100,000 shares 100,000$915K0.32%-200,000Timeline
KURAKURA ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 100,000 shares; 2025Q2: 100,000 shares; 2025Q3: 100,000 shares 100,000$885K0.31%0Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
ATYR PHARMA INCATYR PHARMA INC COM NEWput1,570,200$4.47M+1,347,200
INVESCO QQQ TRINVESCO QQQ TR PUTput250,000$1.56Mnew
SPDR SERIES TRUSTSPDR SERIES TRUST PUTput2,128,300$951K+1,578,300
VERASTEM INCVERASTEM INC COM NEWcall646,500$898Knew
STATE STR SPDR S&P 500 ETF TSTATE STR SPDR S&P 500 ETF T PUTput300,000$718K+50,000
REZOLUTE INCREZOLUTE INC CALLcall263,100$546Knew
IDEAYA BIOSCIENCES INCIDEAYA BIOSCIENCES INC COMcall35,900$237K+15,900
REPLIMUNE GROUP INCREPLIMUNE GROUP INC CALLcall511,400$183K+279,600
ISHARES TRISHARES TR PUTput200,000$20Knew
SCHOLAR ROCK HLDG CORPSCHOLAR ROCK HLDG CORP COMput100,000$10Knew

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
REPLREPLIMUNE GROUP INC900,000$8.36Mshares
URGNUROGEN PHARMA LTD542,366$7.43Mshares
PHVSPHARVARIS N V223,627$3.94Mshares
KALVKALVISTA PHARMACEUTICALS INC157,725$1.78Mshares
INMUNE BIO INCINMUNE BIO INC1,033,200$1.76Mput
CMPSCOMPASS PATHWAYS PLC482,651$1.35Mshares
UROGEN PHARMA LTDUROGEN PHARMA LTD100,000$600Kcall
OVIDOVID THERAPEUTICS INC500,000$165Kshares
CRINETICS PHARMACEUTICALS INCRINETICS PHARMACEUTICALS IN52,700$58Kcall

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001622627-25-000038 base2025-11-13acceptance time not in the bulk data set